Update: Iovance Biotherapeutics Shares Jump After 2026 Revenue Guidance Raised

03:05 PM EDT, 09/29/2026 (MT Newswires) -- (Updates with stock movement in headline and first paragraph.) Iovance Biotherapeutics (IOVA) shares jumped 35% in Tuesday trading after the company raised its 2026 revenue guidance to $410 million to $420 million from its prior outlook of $350 million to $370 million. Analysts polled by FactSet expect $402.8 million. Iovance cited strong US demand for Amtagvi and Proleukin. Price: 14.89, Change: +3.90, Percent Change: +35.48